Lyrinel XL 5mg & 10mg prolonged release tablets

  • Name:

    Lyrinel XL 5mg & 10mg prolonged release tablets

  • Company:
    info
  • Active Ingredients:

    Oxybutynin Hydrochloride

  • Legal Category:

    Product subject to medical prescription which may be renewed (B)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 17/04/20

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 17/4/2020

Click on this link to Download PDF directly

Janssen Sciences Ireland

Company Products

Medicine NameActive Ingredients
Medicine Name Caelyx pegylated liposomal 2mg/ml concentrate for solution for infusion Active Ingredients Doxorubicin hydrochloride
Medicine Name CONCERTA XL 18 mg prolonged-release tablets Active Ingredients Methylphenidate Hydrochloride
Medicine Name Concerta XL 27mg Active Ingredients Methylphenidate Hydrochloride
Medicine Name Concerta XL 36 mg prolonged-release tablets Active Ingredients Methylphenidate Hydrochloride
Medicine Name Dacogen 50 mg powder for concentrate for solution for infusion. Active Ingredients Decitabine
Medicine Name Daktacort 2% 1% Cream Active Ingredients Hydrocortisone, Miconazole nitrate
Medicine Name DARZALEX 1,800 mg solution for injection Active Ingredients Daratumumab
Medicine Name DARZALEX 20 mg/mL concentrate for solution for infusion. Active Ingredients Daratumumab
Medicine Name Durogesic DTrans 100 micrograms/hour Transdermal Patch Active Ingredients Fentanyl
Medicine Name Durogesic DTrans 12 micrograms/hour Transdermal Patch Active Ingredients Fentanyl
Medicine Name Durogesic DTrans 25 micrograms/hour Transdermal Patch Active Ingredients Fentanyl
Medicine Name Durogesic DTrans 50 micrograms/hour Transdermal Patch Active Ingredients Fentanyl
Medicine Name Durogesic DTrans 75 micrograms/hour Transdermal Patch Active Ingredients Fentanyl
Medicine Name Durogesic DTrans Transdermal Patch Active Ingredients Fentanyl
Medicine Name Edurant 25mg film-coated tablets Active Ingredients Rilpivirine Hydrochloride
Medicine Name Erleada 60 mg film coated tablets Active Ingredients Apalutamide
Medicine Name Evra transdermal patch Active Ingredients Ethinylestradiol, Norelgestromin
Medicine Name Gyno-Daktarin 20 mg/g vaginal cream Active Ingredients Miconazole nitrate
Medicine Name Gyno-Pevaryl Once 150mg vaginal pessary Active Ingredients Econazole Nitrate
Medicine Name Haldol Decanoate Active Ingredients Haloperidol decanoate
Medicine Name IMBRUVICA 140 mg, 280 mg, 420 mg and 560 mg film-coated tablets Active Ingredients Ibrutinib
Medicine Name Intelence 200 mg tablets Active Ingredients Etravirine
Medicine Name Invega 3 mg, 6mg, 9mg, 12mg prolonged-release tablets Active Ingredients Paliperidone
Medicine Name Lyrinel XL 5mg & 10mg prolonged release tablets Active Ingredients Oxybutynin Hydrochloride
Medicine Name PARIET 10 mg gastro-resistant tablets Active Ingredients Rabeprazole Sodium
1 - 0 of 58 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 17 April 2020 PIL

Reasons for updating

  • Change to section 6 - what the product contains
  • Change to section 6 - date of revision
  • Change to other sources of information section

Free text change information supplied by the pharmaceutical company

5 mg:

 

Butylhydroxytoluene (E321), cellulose acetate 398-10, hypromellose 5 cp, polyethylene glycol 3350, magnesium stearate, polyethylene oxide 200K, polyethylene oxide 2000K, sodium chloride, black iron oxide (E172), ferric oxide yellow (E172) and lactose anhydrous.

 

Film coat: ferric oxide yellow (E172), hypromellose 3 cp and 6 cp, propylene polyethylene glycol 400, polysorbate 80 and titanium dioxide (E171).

 

Printing Ink: black iron oxide (E172), hypromellose 6 cp and propylene glycol.

 

10 mg:

 

Butylhydroxytoluene (E321), cellulose acetate 398-10, hypromellose 5 cp, polyethylene glycol 3350, magnesium stearate, polyethylene oxide 200K, polyethylene oxide 2000K, sodium chloride, black iron oxide (E172), ferric oxide red (E172) and lactose anhydrous.

 

Film coat: ferric oxide red (E172), hypromellose 3 cp and 6 cp, propylene polyethylene glycol 400, polysorbate 80 and titanium dioxide (E171).

 

Printing Ink: black iron oxide (E172), hypromellose 6 cp and propylene glycol.

 

This medicinal product is authorised in the Member States of the EEA under the following names:

 

Name of the member state

Name of the medicinal product

Greece

LYRINEL

Ireland

LYRINEL XL

Italy

LYRINEL

Portugal

LYRINEL

United Kingdom

LYRINEL XL

Updated on 17 April 2020 SmPC

Reasons for updating

  • Change to section 6.1 - List of excipients
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

5 mg:

butylhydroxytoluene (E321), cellulose acetate 398‑10, hypromellose 5 cp, polyethylene glycol 3350, magnesium stearate, polyethylene oxide 200K, polyethylene oxide 2000K, sodium chloride, black iron oxide (E172), ferric oxide yellow (E172) and lactose anhydrous.

Film coat: ferric oxide yellow (E172), hypromellose 3 cp and 6 cp, propylene polyethylene glycol 400, polysorbate 80 and titanium dioxide (E171).

Printing Ink: black iron oxide (E172), hypromellose 6 cp and propylene glycol.

 

10 mg:

butylhydroxytoluene (E321), cellulose acetate 398‑10, hypromellose 5 cp, polyethylene glycol 3350, magnesium stearate, polyethylene oxide 200K, polyethylene oxide 2000K, sodium chloride, black iron oxide (E172), ferric oxide red (E172) and lactose anhydrous.

Film coat: ferric oxide red (E172), hypromellose 3 cp and 6 cp, propylene polyethylene glycol 400, polysorbate 80 and titanium dioxide (E171).

Printing Ink: black iron oxide (E172), hypromellose 6 cp and propylene glycol.

Updated on 2 May 2019 PIL

Reasons for updating

  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 2 - excipient warnings
  • Change to section 4 - possible side effects

Updated on 2 May 2019 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.9 - Overdose

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 12 April 2019 PIL

Reasons for updating

  • Change to section 4 - how to report a side effect
  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 12 April 2019 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 8 December 2016 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 8 December 2016 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.2

Older People Elderly

Section 4.8

Additional advere events included under 'Not known' frequency category:

Psychiatric disorders - symptoms of depression, dependence (in patients with history of drug or substance abuse)

Gastrointestinal disorders - Pseudo-obstruction in patients at risk (elderly or patients with constipation and treated with other medicinal products that decrease intestinal motility)

Updated on 7 December 2016 PIL

Reasons for updating

  • New PIL for new product

Updated on 7 December 2016 PIL

Reasons for updating

  • Change to section 3 - how to take/use
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 10 February 2016 PIL

Reasons for updating

  • Change to date of revision
  • Change of distributor details

Updated on 3 August 2015 SmPC

Reasons for updating

  • Change to section 6.1 - List of excipients
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Change to names of some of the excipients - no change to actual excipients

Updated on 31 July 2015 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to further information section
  • Change to date of revision

Updated on 1 September 2014 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 2:  Excipient(s) with known effect: Each LYRINEL XL prolonged release tablet contains 0.03 mg lactose.
4.2: administrative change
4.3: administrative change
4.4: Additional information regarding anticholinergics. Additional conditions listed for caution.
4.5: Additional information regarding anticholinergic activity of oxybutynin and regarding concomitant use with CYP3A4 inhibitors
4.6: Use of Lyrinel XL during breastfeeding is not recommended.
4.8: Additional adverse drug reactions listed, wording added regarding reporting of adverse events
5.2: Deletion of second paragraph re pharmacokinetic parameters. Additional of information regarding linearity/non-linearity
10: 31 July 2014

Updated on 29 August 2014 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to information about pregnancy or lactation
  • Change to information about driving or using machinery
  • Change to date of revision

Updated on 8 February 2013 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

1. Addition of new ADRs: Abdominal discomfort, Chest discomfort, Dysphonia, Fluid retention, Frequent bowel movements, Nasal congestion, Oropharyngeal pain, Residual urine and Throat irritation

2. Deletion of 111 terms 

3. Revision of ADRs’ frequencies  

4. Revision of “List of adverse reactions” paragraph to include CT information

5. Deletion of “Undesirable effects noted with other oxybutyn formulations” paragraph

6. Addition of “Description of selected adverse reactions” paragraph

Updated on 8 February 2013 PIL

Reasons for updating

  • Change to side-effects
  • Change to date of revision

Updated on 12 October 2012 SmPC

Reasons for updating

  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Change to section 5.1: Change to information on Paediatric Population
Change to section 5.2: Addition of information on Distribution and Paediatric Popluation. Amendments to Absorption and Metabolism and excretion
Change to section 5.3: Minor administrative change from Preclinical to Non-clinical.
Change to section 10: 09 October 2012

Updated on 29 May 2012 SmPC

Reasons for updating

  • Change to section 4 - Clinical particulars

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.1 Therapeutic indications:

Rewording - deletion of elderly

Section 4.2 Posology and method of administration:

Inclusion of missed dose advice, elderly patients dosage adjustment, info on why to be swallowed whole.     

Section 4.3 Contraindications:

Oxybutynin is replaced by active substance

Section 4.4 Special warnings and precautions for use:

Inclusion of angioedema and related info

Section 4.5 Interactions:

Inclusion of paediatric population paragraph

Section 4.6 Fertility, pregnancy and lactation:

Pregnancy – reworded to not recommended; breast-feeding – reworded to should not be used; addition of fertility paragraph

Section 4.7 Effects on ability to drive:

Addition of has minor influence

Section 4.8 Undesirable effects:

Addition of summary of safety profile intro; addition of anaphylactic reaction and angioedema (not known); hypersensitivity moved from rare to uncommon; addition of paediatric population trial info and adverse reaction table of ADRs.

Section 4.9 Overdose:

Deletion of “Adults: 0.5 to 2.0 mg i.v. slowly, repeated after 5 minutes if necessary, up to a maximum of 5 mg.” and dosage of diazepam.

Updated on 28 May 2012 PIL

Reasons for updating

  • Change to side-effects
  • Change to date of revision
  • Change to improve clarity and readability

Updated on 3 January 2012 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 6.1 - List of excipients
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 2:

For the full list of excipients, see Section 6.1.

Section3:

Lyrinel XL 5 mg prolonged release tablets: Round yellow coloured tablet, approximately 7.5 mm in diameter, printed with “5 XL" on one side in black ink.

Lyrinel XL 10 mg prolonged release tablets: Round pink coloured tablet, approximately 7.5 mm in diameter, printed with “10 XL" on one side in black ink.


Section 6.1:

5 mg

butylhydroxytoluene (E321), cellulose acetate 398-10,, hypromellose 5 cp, macrogol 3350, magnesium stearate, macrogol 200 000, macrogol 2 000 000, sodium chloride, black iron oxide (E172), ferric oxide yellow (E172) and lactose anhydrous.

Film coat: ferric oxide yellow (E172), hypromellose 3 cp and 6 cp, macrogol 400, polysorbate 80 and titanium dioxide (E171).

Printing Ink: black iron oxide (E172), hypromellose 6 cp and propylene glycol.

10 mg

butylhydroxytoluene (E321), cellulose acetate 398-10, hypromellose 5 cp, macrogol 3350, magnesium stearate, macrogol 200 000, macrogol 2 000 000, sodium chloride, black iron oxide (E172), ferric oxide red (E172) and lactose anhydrous.

Film coat: ferric oxide red (E172), hypromellose 3 cp and 6 cp, macrogol 400, polysorbate 80 and titanium dioxide (E171).

Printing Ink: black iron oxide (E172), hypromellose 6 cp and propylene glycol.


Section 10:
December 2011

Updated on 22 December 2011 PIL

Reasons for updating

  • Change to, or new use for medicine
  • Change to further information section
  • Change to date of revision

Updated on 19 September 2011 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.1:

Adults and Elderly

For the symptomatic treatment of urge incontinence and/or increased urinary frequency associated with urgency as may occur in patients with unstable bladder.

Children over the age of 6 years

The symptomatic treatment of detrusor hyperreflexia secondary to a neurogenic condition.

Paediatric population

Oxybutynin hydrochloride is indicated in children over 5 years of age for:

-    Urinary incontinence, urgency and frequency in unstable bladder conditions due to idiopathic overactive bladder or neurogenic bladder disorders (detrusor overactivity).

-    Nocturnal enuresis associated with detrusor overactivity, in conjunction with nondrug therapy, when other treatment has failed.

 

 

Section 4.2

…/

Children over the age of 5 6 years

Initial dose of 5 mg once a day increased in 5 mg increments up to a maximum of 15 mg once a day.

Lyrinel XL is not recommended for use in children below age of 5 6 years, due to a lack of data on safety and efficacy (see sections 5.1 and 5.2).

/…

 

Section 4.4

Paediatric population

Oxybutynin hydrochloride is not recommended for use in children below age 5 years due to insufficient data on safety and efficacy.

There is limited evidence supporting the use of Oxybutynin in children with monosymptomatic nocturnal enuresis (not related to detrusor overactivity).

In children over 5 years of age, Oxybutynin hydrochloride should be used with caution as they may be more sensitive to the effects of the product, particularly the CNS and psychiatric adverse reactions.

Updated on 14 September 2011 PIL

Reasons for updating

  • Change to, or new use for medicine
  • Change to warnings or special precautions for use

Updated on 22 June 2011 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 6.1 - List of excipients
  • Change to section 6.3 - Shelf life
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Change to section 2 - Qualitative and quantitative composition

Excipient: Each Lyrinel XL prolonged release tablet contains 0.03 mg lactose.

 

Change to section 6.1 - List of excipients

5 mg

Butylhydroxytoluene (E321), cellulose acetate 398-10, hypromellose 5 cp , macrogol 3350, magnesium stearate, macrogol 200 000, macrogol 2 000 000, sodium chloride, black iron oxide (E172), ferric oxide yellow (E172) and lactose anhydrous.

Film coat: ferric oxide yellow (E172), hypromellose 3 cp and 6 cp, macrogol 400, polysorbate 80 and titanium dioxide (E171)

Printing Ink: black iron oxide (E172), hypromellose 6 cp, propylene glycol and purified water..

10 mg

Butylhydroxytoluene (E321), cellulose acetate 398-10, hypromellose 5 cp, macrogol 3350, magnesium stearate, macrogol 200 000, macrogol 2 000 000, sodium chloride, black iron oxide (E172), ferric oxide yellow (E172) and lactose anhydrous.

Film coat: ferric oxide red (E172), hypromellose 3 cp and 6 cp, macrogol 400, polysorbate 80 and titanium dioxide (E171)

Printing Ink: black iron oxide (E172), hypromellose 6 cp, propylene glycol and purified water..

 

Change to section 6.3 - Shelf life

Lyrinel XL 5mg: 2 years

Lyrinel XL 10mg: 18 months

 

Change to section 6.6 - Special precautions for disposal and other handling

Do not remove or swallow the sachet of granules in the bottle. This contains desiccant, which keeps the tablets dry

 

Change to section 9 - Date of renewal of authorisation

27th August 2004/14th June 2010

 

Change to section 10 - Date of revision of the text

June 2011

Updated on 20 June 2011 PIL

Reasons for updating

  • Change of trade or active ingredient name
  • Change to, or new use for medicine
  • Change to storage instructions
  • Change to further information section
  • Change to date of revision

Updated on 1 December 2010 PIL

Reasons for updating

  • Change to storage instructions

Updated on 25 September 2009 PIL

Reasons for updating

  • Change to MA holder contact details

Updated on 7 July 2009 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company



Change to section 4.8 – Undesirable effects

Addition of memory impairment as an ADR

Change to section 10 – Date of revision of text

June 2009

Updated on 29 June 2009 PIL

Reasons for updating

  • Change to date of revision
  • Change due to harmonisation of PIL

Updated on 6 November 2008 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Change to section 4.8 Undesirable effects

Updated Table

Change to section 10 Date of revision of text

October 2008

Updated on 19 August 2008 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

X

Change to section 7 – Marketing Authorisation Holder

Address changed to new site address

X

Change to section 10 – Date of revision of text

August 2008

Updated on 19 August 2008 PIL

Reasons for updating

  • Change to date of revision
  • Change to marketing authorisation holder address

Updated on 5 June 2008 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.9 - Overdose
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Change to section 1 – trade name

NAME OF THE MEDICINAL PRODUCT

Minor Change

Change to section 2 – quantitative and qualitative composition

Minor Change

Change to section 3 – pharmaceutical form

Minor Change

Change to section 4.2 – Posology and |Method of Administration

Minor Change

Change to section 4.3 – Contra-indications

Minor Change

Change to section 4.4 – Special Warnings and Precautions for Use

Major Change

Change to section 4.5 –Interaction with other medicinal products and other forms of interaction

Minor Change

Change to section 4.6 – Pregnancy and Lactation

Minor Change

Change to section 4.7 - Effects on Ability to Drive and Use Machines

Minor Change

Change to section 4.9 - Overdose

Minor Change

Change to section 5.2 - Pharmacokinetic properties

Minor Change

Change to section 5.3 - Preclinical Safety Data

Minor Change

Change to section 10 – Date of revision of text

Change to June 2008

Updated on 14 November 2006 SmPC

Reasons for updating

  • Correction of spelling/typing errors

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 7 November 2006 PIL

Reasons for updating

  • Change to, or new use for medicine
  • Change of contraindications
  • Change to side-effects
  • Change to date of revision

Updated on 6 November 2006 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

4.1

Therapeutic Indications

New indication added

 

Children over the age of 6 years

The symptomatic treatment of detrusor hyperreflexia secondary to a neurogenic condition.

4.2

Posology and method of administration

Text deleted

 

The safety and efficacy of Lyrinel XL have not been established in patients under 18 years. The use of Lyrinel XL in children is not recommended.

 

Text inserted

 

Children over the age of 6 years

Initial dose of 5mg once a day increased in 5mg increments up to a maximum of 15mg once a day.

The safety and efficacy of Lyrinel XL has not been established in patients less than 6 years.

4.3

Contraindications

Text inserted

 

Porphyria

4.4

Special Warnings and Precautions for Use

Text inserted

 

Heat stroke added to following sentence

 

When oxybutynin is used in patients with fever or in high environmental temperatures, this can cause heat prostration, or heat stroke due to decreased sweating.

 

 

4.8

Undesirable effects

Text inserted

 

Night terror added to following sentence

 

Additional rare adverse events reported from worldwide post-marketing experience with oxybutynin chloride include hallucinations, convulsions, night terror and erectile dysfunction.

 

5.1

Pharmacodynamic properties

Text inserted

 

Children over the age of 6 years: in children with detrusor hyperreflexia secondary to a neurogenic condition, oxybutynin, in combination with clean intermittent urinary catheterisation, has been shown in open uncontrolled studies to increase mean urine volume per catherisation, increase maximum cystometric capacity and decrease mean detrusor pressure at maximum cystometric capacity.

5.2

Pharmacokinetic properties

Text inserted

 

Limited data suggest that the pharmacokinetics of Lyrinel XL is similar in adults and children aged 8 years and above.  The pharmacokinetics of Lyrinel XL have not been investigated in patients with renal or hepatic insufficiency.

 

Text deleted

 

The pharmacokinetics of Lyrinel XL tablets have not been investigated in children, nor in patients with renal or hepatic insufficiency.

10.

DATE OF REVISION OF THE TEXT

Changed to

 

18th July 2006

 

 

 

Updated on 21 November 2005 PIL

Reasons for updating

  • Change to drug interactions
  • Change to side-effects

Updated on 18 November 2005 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 5 April 2005 PIL

Reasons for updating

  • New PIL for new product

Updated on 4 April 2005 SmPC

Reasons for updating

  • New SPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)